Enhua pharmaceutical heavy new drug remifentanil hydrochloride for injection is approved within one month

People from the company told DZH news that the approved production of remifentanil is a high probability event He pointed out that the company's existing plant can be used for product production, and production can be arranged after obtaining approval documents At the same time, remifentanil can be put on the market without bidding, and the product will be put on the market soon after being approved Remifentanil is mainly used in the treatment of general anesthesia induction and maintenance analgesia in general anesthesia Its analgesic effect is similar to that of fentanyl, and it has less side effects on respiratory inhibition, so it has a substitution effect on fentanyl CFDA website information shows that at present, only humanwell Pharmaceutical (600079 SH) and Sinopharm group have the approval documents of the drug in China, of which humanwell pharmaceutical products account for the vast majority of the market share According to the above company, the company has made channel preparation for the listing of remifentanil through the sales of fentanyl in the early stage, and the product pricing of remifentanil after the listing will be similar to that of humanwell pharmaceutical Enhua Pharmaceutical Co., Ltd is the leading drug manufacturer in the field of central nervous system in China Remifentanil is one of the heavyweight anesthetic products reserved by the company It is a high probability event that the company expects remifentanil to grow into more than 100 million varieties In the first half of 2014, the total operating revenue of narcotic drugs of Enhua pharmaceutical industry reached 285 million Published by: Ding Yingying / Gu Meiyi reviewed by: Xu Xueli * the information in this article is for reference only, and the investors shall bear the operational risk accordingly (official wechat interactive DZH News Shanghai station Tel.: + 86-21-2021 9988-31065 Beijing station Tel.: + 86-10-5799 5701 weibo.com/dzhnews) for more stock news, please log in to wisdom 365.